Abstracts

DOLUTEGRAVIR INTERACTIONS WITH ARTEMETHER-LUMEFANTRINE AND AMODIAQUINE-ARTESUNATE

We investigated potential drug-drug interactions between the most commonly used artemisinin-containing therapies artmether-lumefantrine (AL) or artesunate-amodiaquine (AS-AQ) and dolutegravir (DTG). We undertook two pharmacokinetic (PK) studies in healthy Ugandan volunteers, using standard clinical treatment doses of AL and AS-AQ and 50mg of DTG once daily given with food. Rich PK sampling was performed after the…

TENOFOVIR HIV-1 PLASMA PROPHYLACTIC CONCENTRATION: iPREX,VOICE,PARTNERS META-ANALYSIS

The results from pre-exposure prophylaxis (PrEP) efficacy trials that evaluated tenofovir disoproxil fumarate (TDF) have hypothesized that individuals who acquired HIV-1 infection had low adherence based on lower rates of quantifiable/protective tenofovir (TFV) levels. However, prophylactic TFV plasma levels are still not fully characterized. Our aim was to perform individual level data meta-analysis from double-blinded…

PERSISTENT LOW-LEVEL VIREMIA IS ASSOCIATED WITH LOW PROTEASE INHIBITOR LEVELS IN HAIR

HIV-infected patients on combination antiretroviral therapy (ART) may experience episodes of low-level viremia (LLV). Persistent LLV is associated with antiretroviral (ARV) drug resistance and regimen failure, but its etiology and optimal management are unclear. We evaluated the association between LLV and ARV concentration in hair, a measure of long-term ARV exposure. HIV-infected women in the…

PHARMACOLOGIC MEASURES OF PrEP ADHERENCE AMONG HIGH-RISK MSM IN HPTN 067

The effectiveness of oral emtricitabine (FTC)/tenofovir (TFV) disoproxil-fumarate pre-exposure prophylaxis (PrEP) is highly dependent on adherence. Given limitations of self-reported adherence, pharmacologic measures are useful for understanding patterns of adherence and identifying predictors of consistent PrEP use. We analyzed data from HPTN 067, a trial of intermittent and daily PrEP completed in 2014. We included…

MORTALITY/MORBIDITY AFTER INITIATING ART WITH CD4 <100 CELLS/UL IN THE REALITY TRIAL

In sub-Saharan Africa, 20-25% of those starting ART have CD4<100 cells/ul; ~10% die within 3 months. We investigated the contribution and timing of different causes of mortality/morbidity in the REALITY trial (ISRCTN43622374). Patients starting ART were randomized to enhanced-prophylaxis against infections (cotrimoxazole [CTX] plus 12 weeks isoniazid+fluconazole, single-dose albendazole, 5-days azithromycin (AZ); Px+) vs CTX…

AGE, GENDER, AND RACE ANALYSES OF D/C/F/TAF IN HIV-1 TREATMENT NAÏVE PATIENTS

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the only single-tablet regimen in development for HIV-1 infection that contains darunavir and F/TAF. AMBER evaluated the efficacy and safety of D/C/F/TAF 800/150/200/10 mg versus control (D/C+F/tenofovir disoproxil fumarate [TDF]) in antiretroviral treatment (ART)-naïve, HIV-1–infected adults. We present Week 48 results based on age, gender, and race. In AMBER, a phase…